Think of Enterprise Value as the theoretical takeover price. It is more comprehensive than market capitalization (Market Cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash, cash equivalents, and marketable securities.
EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, Sartorius Stedim Biotech's Enterprise Value is $21,976 Mil.
Sartorius Stedim Biotech's EBIT for the trailing twelve months (TTM) ended in Mar. 2026 was $581 Mil. Therefore, Sartorius Stedim Biotech's EV-to-EBIT ratio for today is 37.84.
*** Please note that the current Enterprise Value is calculated using the current market capitalization and the most recently available financial data. If key financial fields—Long-Term Debt & Capital Lease Obligation and Short-Term Debt & Capital Lease Obligation—are recorded as null in the latest reporting period, our data vendor will default to using data from the prior period with valid entries.
Sartorius Stedim Biotech (OTCPK:SRTOY) Enterprise Value Explanation
When an investor buy a company, the investor needs to pay not only the common shares, he/she also needs to pay the shareholders of Preferred Stocks. He also assumes the debt of the company, and receives the cash on the company's balance sheet.
If a company has more cash than debt, the investor actually pays less than the Market Cap because he immediately owns the cash once the transaction goes through.
The market value of Preferred Stock needs to be added to the market value of common stocks in the calculation of Enterprise Value.
For the companies with the same Market Cap, the smaller the Enterprise Value is, the cheaper the company is.
Enterprise Value can be negative when the company's net cash is more than its Market Cap. In this case the investor is basically getting the company for free and get paid for that.
1. EV-to-EBIT is calculated as Enterprise Value divided by its EBIT.
Sartorius Stedim Biotech's EV-to-EBIT for today is
Sartorius Stedim Biotech's current Enterprise Value is $21,976 Mil.
Sartorius Stedim Biotech's EBIT for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $581 Mil.
2. EV-to-EBITDA is calculated as Enterprise Value divided by its EBITDA.
Sartorius Stedim Biotech's EV-to-EBITDA for today is:
Sartorius Stedim Biotech's current Enterprise Value is $21,976 Mil.
Sartorius Stedim Biotech's EBITDA for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $955 Mil.
Sartorius Stedim Biotech's current Enterprise Value is $21,976 Mil.
Sartorius Stedim Biotech's Revenue for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $3,472 Mil.
Sartorius Stedim Biotech's current Enterprise Value is $21,976 Mil.
Sartorius Stedim Biotech's Cash Flow from Operations for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $892 Mil.
Sartorius Stedim Biotech's current Enterprise Value is $21,976 Mil.
Sartorius Stedim Biotech's Free Cash Flow for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $429 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Sartorius Stedim Biotech Enterprise Value Related Terms
Sartorius Stedim Biotech Enterprise Value Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
SRTOY vs ISRG, BDX, MDLN: Enterprise Value Comparison
For the Medical Instruments & Supplies subindustry, Sartorius Stedim Biotech's Enterprise Value, along with its competitors' market caps and Enterprise Value data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Sartorius Stedim Biotech Enterprise Value vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Sartorius Stedim Biotech's Enterprise Value distribution charts can be found below:
* The bar in red indicates where Sartorius Stedim Biotech's Enterprise Value falls into.
Sartorius Stedim Biotech Enterprise Value Calculation
Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash, cash equivalents, and marketable securities.
Sartorius Stedim Biotech's Enterprise Value for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Sartorius Stedim Biotech (SRTOY) has a Enterprise Value of $21,976 Mil as of Jun. 28, 2026. Enterprise value equals the sum of market cap, debt and preferred shares less cash and equivalents. View historical data on Sartorius Stedim Biotech and its competitors.
Is Sartorius Stedim Biotech's Enterprise Value too high?
Sartorius Stedim Biotech's current Enterprise Value is $21,976 Mil. Overall, Sartorius Stedim Biotech has a GF Score™ of 82/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Sartorius Stedim Biotech's Enterprise Value compare to ISRG and BDX?
Sartorius Stedim Biotech's Enterprise Value of $21,976 Mil can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Enterprise Value for a Medical Devices & Instruments company?
A good Enterprise Value depends on the Medical Devices & Instruments industry context. However, Enterprise Value should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Enterprise Value mean?
A high Enterprise Value can signal that a stock is expensive relative to its fundamentals. Enterprise value equals the sum of market cap, debt and preferred shares less cash and equivalents. View historical data on Sartorius Stedim Biotech and its competitors. Sartorius Stedim Biotech's current Enterprise Value is $21,976 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Sartorius Stedim Biotech stock overvalued right now?
Based on GuruFocus' analysis, Sartorius Stedim Biotech (SRTOY) is currently considered Modestly Undervalued. The stock's GF Value™ is $23.65, compared to a current price of $20.09 — trading 15.1% below its estimated fair value. The current Enterprise Value is $21,976 Mil. Sartorius Stedim Biotech's overall GF Score™ is 82/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Enterprise Value calculated?
Enterprise Value is calculated from a company's financial statements. For Sartorius Stedim Biotech (SRTOY), the current Enterprise Value is $21,976 Mil as of Jun. 28, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Sartorius Stedim Biotech (SRTOY) Overvalued in 2026?
Based on GuruFocus' analysis, Sartorius Stedim Biotech stock appears to be undervalued.
The current stock price of $20.09 is trading 15.1% below its estimated GF Value™ of $23.65.
GuruFocus considers Sartorius Stedim Biotech to be Modestly Undervalued.
Key valuation signals for SRTOY:
Enterprise Value: $21,976 Mil
GF Value™: $23.65 vs. price of $20.09 (15.1% below fair value)
No single metric tells the full story. See the SRTOY stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Sartorius Stedim Biotech is a leading provider of bioprocessing solutions. It sells equipment and consumables for fermentation, filtration, fluid management, purification, and cell culture media for manufacturing biologic drugs and has a focus on single-use technology. It is a subsidiary of Sartorius AG, which has 71.5% ownership and 83% voting control. The business is geographically diverse, with 35% of sales from the Americas, 42% from Europe, the Middle East, and Africa, 15% from Asia excluding China, and 8% from China.
82GF Score
Get the complete analysis for SRTOY
Enterprise Value is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SRTOY has been successfully added to your 
